PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
TG Therapeutics, Inc. (TGTX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US88322Q1085

CUSIP

88322Q108

Sector

Healthcare

IPO Date

Dec 14, 1995

Highlights

Market Cap

$4.69B

EPS (TTM)

-$0.10

Total Revenue (TTM)

$220.82M

Gross Profit (TTM)

$197.58M

EBITDA (TTM)

$17.39M

Year Range

$12.84 - $36.84

Target Price

$40.75

Short %

19.26%

Short Ratio

8.95

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
TGTX vs. ACIC TGTX vs. QQQ TGTX vs. GRBK TGTX vs. QQQM TGTX vs. VOO TGTX vs. RYTM TGTX vs. MIRM TGTX vs. SPY TGTX vs. VGT TGTX vs. RKLB
Popular comparisons:
TGTX vs. ACIC TGTX vs. QQQ TGTX vs. GRBK TGTX vs. QQQM TGTX vs. VOO TGTX vs. RYTM TGTX vs. MIRM TGTX vs. SPY TGTX vs. VGT TGTX vs. RKLB

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in TG Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-40.00%-20.00%0.00%20.00%40.00%60.00%AugustSeptemberOctoberNovemberDecember2025
33.33%
5.95%
TGTX (TG Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

TG Therapeutics, Inc. had a return of -6.98% year-to-date (YTD) and 31.46% in the last 12 months. Over the past 10 years, TG Therapeutics, Inc. had an annualized return of 5.22%, while the S&P 500 had an annualized return of 11.22%, indicating that TG Therapeutics, Inc. did not perform as well as the benchmark.


TGTX

YTD

-6.98%

1M

-17.48%

6M

40.63%

1Y

31.46%

5Y*

16.59%

10Y*

5.22%

^GSPC (Benchmark)

YTD

0.47%

1M

-2.98%

6M

5.95%

1Y

24.05%

5Y*

12.57%

10Y*

11.22%

*Annualized

Monthly Returns

The table below presents the monthly returns of TGTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-4.92%6.03%-11.67%-10.19%19.33%9.14%11.07%18.88%-0.43%7.14%38.87%-13.51%76.23%
202328.74%5.19%-6.12%65.09%7.25%-6.72%-16.71%-49.40%-20.15%-7.54%65.72%33.33%44.38%
2022-39.11%-14.69%-3.65%-27.02%-36.31%-3.85%40.94%19.03%-16.97%-1.69%51.55%34.13%-37.74%
2021-7.21%-9.32%10.12%-7.24%-22.01%11.24%-9.80%-22.64%22.94%-6.19%-51.31%25.00%-63.48%
202028.02%-11.68%-21.59%19.51%58.59%4.45%0.51%26.69%7.88%-5.57%16.11%77.30%368.65%
20190.00%65.85%18.24%-1.12%-21.13%37.96%-13.41%-17.09%-9.58%21.64%19.91%35.53%170.73%
201840.24%21.74%1.43%1.06%-6.62%-1.87%-10.65%8.09%-55.91%-18.75%10.77%-18.65%-50.00%
20173.23%18.75%104.39%-5.15%1.81%-10.67%14.43%10.43%-6.69%-31.22%5.52%-4.65%76.34%
2016-31.52%1.96%2.28%6.92%-17.45%-19.41%-2.48%7.45%21.89%-30.88%7.48%-19.13%-61.02%
2015-10.10%1.90%6.69%-9.82%12.75%5.40%5.18%-29.63%-17.92%22.72%6.55%-9.48%-24.68%
201453.85%10.00%4.55%-22.75%22.51%43.80%-15.76%7.21%25.83%3.00%35.76%6.17%306.15%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of TGTX is 69, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of TGTX is 6969
Overall Rank
The Sharpe Ratio Rank of TGTX is 6969
Sharpe Ratio Rank
The Sortino Ratio Rank of TGTX is 7171
Sortino Ratio Rank
The Omega Ratio Rank of TGTX is 6868
Omega Ratio Rank
The Calmar Ratio Rank of TGTX is 6666
Calmar Ratio Rank
The Martin Ratio Rank of TGTX is 6868
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for TG Therapeutics, Inc. (TGTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for TGTX, currently valued at 0.62, compared to the broader market-4.00-2.000.002.000.622.03
The chart of Sortino ratio for TGTX, currently valued at 1.44, compared to the broader market-4.00-2.000.002.004.001.442.71
The chart of Omega ratio for TGTX, currently valued at 1.17, compared to the broader market0.501.001.502.001.171.37
The chart of Calmar ratio for TGTX, currently valued at 0.42, compared to the broader market0.002.004.006.000.433.04
The chart of Martin ratio for TGTX, currently valued at 2.19, compared to the broader market-10.000.0010.0020.002.1912.93
TGTX
^GSPC

The current TG Therapeutics, Inc. Sharpe ratio is 0.62. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of TG Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00AugustSeptemberOctoberNovemberDecember2025
0.62
2.03
TGTX (TG Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


TG Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-99.98%
-2.98%
TGTX (TG Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the TG Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the TG Therapeutics, Inc. was 100.00%, occurring on Dec 29, 2011. The portfolio has not yet recovered.

The current TG Therapeutics, Inc. drawdown is 99.98%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Oct 23, 19973241Dec 29, 2011
-51.9%Feb 29, 1996244Apr 11, 1997110Oct 13, 1997354
-13.7%Feb 9, 19967Feb 20, 19962Feb 22, 19969
-13.21%Jan 15, 19963Jan 17, 199612Feb 2, 199615
-10.2%Dec 29, 19951Dec 29, 19956Jan 10, 19967

Volatility

Volatility Chart

The current TG Therapeutics, Inc. volatility is 17.63%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%AugustSeptemberOctoberNovemberDecember2025
17.63%
4.47%
TGTX (TG Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of TG Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for TG Therapeutics, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab